Therapeutic Solutions CEO tries to avoid “dilution” in next steps for JadiCell
Aug. 06, 2021 9:48 AM ETTherapeutic Solutions International, Inc. (TSOI)Therapeutic Solutions International, Inc. (TSOI)By: Dulan Lokuwithana, SA News Editor
Pandemic Illness in Lung
sefa ozel/iStock via Getty Images
In laying out plans for funding the next phase of development for the company’s potential COVID-19 therapy JadiCell, Timothy Dixon CEO of Therapeutic Solutions (OTCPK:TSOI -11.1%) says the dilution of share ownership is out of the question.
In a blog post on Friday, Dixon wrote “its not even on my mind today (dilution),” as the company attempts to seek government funding for further clinical development of JadiCell which has received FDA clearance to start a Phase 3 pivotal trial to treat COVID-linked lung failure.
The CEO said the company targets emergency use authorizations for the treatment not only in the U.S. but also overseas.
“One EUA deal and the rest will fall like domino's and we will serve humanity and we will serve you,” he added.
In June, Therapeutic Solutions (OTCPK:TSOI) posted pre-clinical data supporting the efficacy of JadiCell in reversing neuroinflammation-driven brain damage in an animal model following COVID-19 infection.
Now read: Federal court rules in AstraZeneca's favor on 340B discounted drugs program
Never miss the best stock ideas!
Stock Ideas Newsletter
266,087 subs.
Recommended For You
Buy Alert: 2 Dividend Stocks To Double Your Retirement Income
Rida Morwa
Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
Biologics
Palantir: Brace For Impact, Earnings Are Due Out Next Week
Business Quant
